MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
SARS-CoV-2 and COVID-19 Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

4,166 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
4,166 works in the cohort · of 4,299,418page 17 of 84

Labels cover 17 of 4,166 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 4,166 of 4,166 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

fundno affunlabeled
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
Zhigang Liu, Kaixing Le, Xin Zhou, James L. Alexander, Simeng Lin, Claire Bewshea +677 more
2022· article· en· ˜The œLancet. Gastroenterology & hepatology· Medicine
machine prediction:candidate · noneconsensus · none
35
citations
affaboutunlabeled
COVID-19 vaccine immunogenicity in people with HIV
Cecilia T. Costiniuk, Joel Singer, Terry Lee, Marc‐André Langlois, Corey Arnold, Yannick Galipeau +24 more
2022· article· en· AIDS· Medicine
machine prediction:candidate · noneconsensus · none
34
citations
affno abstractunlabeled
The Antigenic Anatomy of SARS-CoV-2 Receptor Binding Domain
Wanwisa Dejnirattisai, Daming Zhou, Helen M. Ginn, Helen M. E. Duyvesteyn, Piyada Supasa, James Brett Case +47 more
2020· article· en· SSRN Electronic Journal· Medicine
machine prediction:candidate · noneconsensus · none
33
citations
afffundunlabeled
Targeting SARS-CoV-2 Non-Structural Proteins
W.G. Tam, Ana C. Lorenzo‐Leal, Luis R. Hernández, Horacio Bach
2023· review· en· International Journal of Molecular Sciences· Medicine
machine prediction:candidate · noneconsensus · none
33
citations

How this was built: Screen · Findings · About